Scott B Hoyt

This inventor holds 14 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 9 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Elexopharm Gmbh, Merck Canada Inc.. Active years: 2011-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Scott B Hoyt. Retrieved from https://idiyas.com/inventor/scott-b-hoyt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 5)

% Patents Active = 85.7

CIPO Patents = 2

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 7.3

ph-index = 2

Forward Citations = 22(Granted Patents)

Location History:

Hoboken, NJ (US) (2011 - 2018)
Arlington, VA (US) (2019 - 2021)

Company Filing History:

14 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2011-2021

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11008313 - Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders (2021-05-18),

2. 10806724 - Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use (2020-10-20),

3. 10335399 - Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2—negative allosteric modulators, compositions, and their use (2019-07-02),

4. 10072003 - Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use (2018-09-11),

5. 9844553 - Pyrazolopyridyl compounds as aldosterone synthase inhibitors (2017-12-19),

6. 9567333 - Triazolopyridyl compounds as aldosterone synthase inhibitors (2017-02-14),

7. 9522141 - Indazole compounds as aldosterone synthase inhibitors (2016-12-20),

8. 9518055 - Imidazopyridyl compounds as aldosterone synthase inhibitors (2016-12-13),

9. 9382226 - Aldosterone synthase inhibitors (2016-07-05),

10. 9351973 - Pyrazolopyridyl compounds as aldosterone synthase inhibitors (2016-05-31),

11. 9193724 - Triazolopyridyl compounds as aldosterone synthase inhibitors (2015-11-24),

12. 9073929 - Aldosterone synthase inhibitors (2015-07-07),

13. 8273749 - N-substituted oxindoline derivatives as calcium channel blockers (2012-09-25),

14. 7888345 - Benzaepinones as sodium channel blockers (2011-02-15),

Title: Scott B. Hoyt – A Pioneer in Pharmaceutical Innovations

Introduction

Scott B. Hoyt, based in Hoboken, NJ, is an accomplished inventor known for his significant contributions to pharmaceutical science. With a total of 14 patents to his name, Hoyt's work primarily focuses on the development of innovative compounds aimed at treating cardiovascular diseases and neurological disorders.

Latest Patents

One of his latest patents involves "Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders." This invention relates to compounds that can induce degradation of the PCSK9 protein, which is crucial for the treatment of various cardiovascular conditions, including atherosclerosis and hypercholesterolemia. Additionally, this patent outlines methods for labeling and detecting PCSK9 in biological samples, paving the way for advanced diagnostics.

Another notable patent is centered around "Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators." The compounds described in this invention show promise as mGluR2 inhibitors and can potentially treat a range of diseases, including Alzheimer's disease, cognitive impairment, and various mood disorders. The invention emphasizes the pharmaceutical compositions that can help in effectively administering the therapeutic agents.

Career Highlights

Throughout his career, Scott B. Hoyt has worked with esteemed companies such as Merck Sharp & Dohme Corporation and Merck Canada Inc. His work at these organizations has not only strengthened the foundations of pharmaceutical innovations but also enhanced the quality of life for many patients through advanced therapeutic solutions.

Collaborations

Hoyt has collaborated with distinguished colleagues like Clare London and Yusheng Xiong. These partnerships have played a significant role in the evolution of his inventions, fostering a collaborative environment that encourages the exchange of ideas and expertise in the field of pharmaceuticals.

Conclusion

Scott B. Hoyt's contributions to innovation in the pharmaceutical industry are commendable. His 14 patents reflect his dedication to improving human health through groundbreaking inventions. As research and development continue to push the boundaries of science, Hoyt's work stands as a testament to the importance of innovation in addressing complex health challenges.

Profile summary based on public USPTO records.